Skip to main content

Table 1 Clinical background: UGT1A1 genotype and clinical characteristics

From: UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study

UGT1A1   Total UGT1A1 wild-type UGT1A1 polymorphism (hetero/homo type) P-value
Number (%)   51 24 (47.0%) 23/4 (45.1%/7.8%)  
Age, years Average (min-max) 52.2 52.3 (36–64) 52.1 (29–78) 0.96
FIGO stage IB1–2 24 (47.1%) 11 13 0.56
IIA 2 (3.9%) 0 2
IIB 25 (49.0%) 13 12
Lymph node metastasis None 38 (74.5%) 17 21 0.44
Pelvic nodes 11 (21.5%) 5 6
Para-aortic nodes 2 (3.9%) 2 0
  1. FIGO Federation of Gynecology and Obstetrics, UGT1A1 Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1